<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04768881</url>
  </required_header>
  <id_info>
    <org_study_id>XPORT-MEL-033</org_study_id>
    <nct_id>NCT04768881</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of Selinexor in Combination With Pembrolizumab in Recurrent Advanced Melanoma</brief_title>
  <official_title>A Phase 2 Open-Label Multicenter Study to Evaluate the Safety and Efficacy of Selinexor in Combination With Pembrolizumab in Recurrent Advanced Melanoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Karyopharm Therapeutics Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Karyopharm Therapeutics Inc</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Approximately 40 participants with locally advanced or metastatic melanoma will be enrolled&#xD;
      in 20 sites in the United States into 1 of the following 2 arms: Primary resistance to&#xD;
      initial checkpoint inhibitor (CPI) therapy in Arm A and Acquired resistance to initial CPI&#xD;
      therapy in Arm B. Participants who have disease progression (PD) after discontinuation of&#xD;
      CPIs, especially in neoadjuvant or adjuvant therapy, will be considered to have acquired&#xD;
      resistance in this study. Participants will receive study treatment (Selinexor and&#xD;
      Pembrolizumab) until PD, intolerable toxicity or withdrawal from the study, whichever occurs&#xD;
      first.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 12, 2021</start_date>
  <completion_date type="Anticipated">November 2024</completion_date>
  <primary_completion_date type="Anticipated">May 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Response Rate (ORR)</measure>
    <time_frame>Up to 24 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression-free Survival (PFS)</measure>
    <time_frame>Up to 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>Up to 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complete Response Rate (CRR)</measure>
    <time_frame>Up to 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response (DOR)</measure>
    <time_frame>Up to 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease Control Rate (DCR)</measure>
    <time_frame>Up to 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Treatment-emergent Adverse Events (TEAEs) and Serious TEAEs</measure>
    <time_frame>Baseline up to 30 Days after End of Treatment (EoT) (EoT: Less than or equal to [≤28] days post-treatment discontinuation)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Clinically Significant Safety Observations: Clinical Laboratory (Hematology and Chemistry), Vital Signs and Physical Examination</measure>
    <time_frame>Baseline up to 30 Days after EoT (EoT: ≤28 days post-treatment discontinuation)</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Locally Advanced Unresectable or Metastatic Melanoma</condition>
  <arm_group>
    <arm_group_label>Arm A: Primary resistance to Initial CPI Therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive a dose of 80 milligrams (mg) selinexor orally once weekly (QW) and a dose of pembrolizumab 400 mg intravenously (IV) once in every six weeks (Q6W), both on Day 1 of a 6-week cycle until progressive disease (PD), intolerable toxicity or withdrawal from the study, whichever occurs first.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B: Acquired Resistance to Initial CPI Therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive a dose of 80 mg selinexor orally once weekly (QW) and a dose of pembrolizumab 400 mg IV Q6W, both on Day 1 of a 6-week cycle until PD, intolerable toxicity or withdrawal from the study, whichever occurs first.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Selinexor</intervention_name>
    <description>Dose and formulation: 80 mg (4 tablets of 20 mg)</description>
    <arm_group_label>Arm A: Primary resistance to Initial CPI Therapy</arm_group_label>
    <arm_group_label>Arm B: Acquired Resistance to Initial CPI Therapy</arm_group_label>
    <other_name>KPT-330</other_name>
    <other_name>XPOVIO™</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pembrolizumab</intervention_name>
    <description>Dose and formulation: 400 mg (25 milligrams per milliliter [mg/mL]) Solution</description>
    <arm_group_label>Arm A: Primary resistance to Initial CPI Therapy</arm_group_label>
    <arm_group_label>Arm B: Acquired Resistance to Initial CPI Therapy</arm_group_label>
    <other_name>Keytruda™</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age greater than or equal to (≥) 18 years at the time of informed consent.&#xD;
&#xD;
          -  Participant must have a histologically confirmed diagnosis of locally advanced&#xD;
             unresectable stage III or metastatic stage IV melanoma not amenable to local therapy.&#xD;
&#xD;
               1. Participants must have confirmed PD per Response Evaluation Criteria in Solid&#xD;
                  Tumors (RECIST) on or within 12 weeks of the last dose of anti-PD-1/L1&#xD;
                  monotherapy or combination therapy (including relatlimab or other anti-LAG-3 mAb)&#xD;
                  per Society for Immunotherapy in Cancer Guidelines (Kluger,2020).&#xD;
&#xD;
               2. Arm A (primary resistance): participant has disease progression after receiving&#xD;
                  at least 6 weeks of prior anti-PD-1/L1 mAb with the best response as PD, or&#xD;
                  stable disease (SD) less than (&lt;) 6 month (participants with a partial response&#xD;
                  [PR] or complete response [CR] who have disease progression within 6 months will&#xD;
                  be considered to have primary resistance in this study).&#xD;
&#xD;
               3. Arm B (secondary/acquired resistance): participant has disease progression after&#xD;
                  receiving at least 6 months of prior anti-PD-1/L1 mAb with the best response as&#xD;
                  CR, PR, or SD greater than (&gt;) 6 months (participants who have disease&#xD;
                  progression after neoadjuvant or adjuvant therapy, will be considered to have&#xD;
                  secondary resistance in this study).&#xD;
&#xD;
               4. Participants who progress on or within 12 weeks after elective discontinuation of&#xD;
                  anti-PD-1/L1 mono or combination treatment in the absence of PD or treatment&#xD;
                  limiting toxicity must have confirmed PD per RECIST.&#xD;
&#xD;
          -  Participants should have at least 1 prior line of CPI therapy but no more than 2.&#xD;
&#xD;
          -  Measurable disease according to RECIST v1.1.&#xD;
&#xD;
          -  Participants with stable previously treated brain metastases are permitted in this&#xD;
             study.&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status less than or equal to (≤)&#xD;
             1.&#xD;
&#xD;
          -  Adequate bone marrow function at screening, defined as:&#xD;
&#xD;
               1. Absolute neutrophil count (ANC) ≥1.5 * 10^9 per liter (L).&#xD;
&#xD;
               2. Hemoglobin ≥10 gram per deciliter (gm/dL) (≥6.2 millimoles per liter [mmol/L]).&#xD;
&#xD;
               3. Platelet count ≥100 * 10^9/L.&#xD;
&#xD;
          -  Serum direct bilirubin ≤1.5 * upper limit of normal (ULN); aspartate transaminase&#xD;
             (AST) and alanine transaminase (ALT) ≤2.5 * ULN (with confirmed liver metastases: AST&#xD;
             and ALT ≤5 * ULN).&#xD;
&#xD;
          -  Calculated creatinine clearance (CrCl) ≥15 milliliters per minute (mL/min) based on&#xD;
             the Cockcroft and Gault formula.&#xD;
&#xD;
          -  Female participants of childbearing potential must have a negative serum pregnancy&#xD;
             test at screening and agree to use highly effective methods of contraception&#xD;
             throughout the study and for at least four months following the last dose of study&#xD;
             treatment. Childbearing potential excludes: Age &gt;50 years and naturally amenorrhoeic&#xD;
             for &gt;1 year, or previous bilateral salpingo-oophorectomy, or hysterectomy.&#xD;
&#xD;
          -  Male participants who are sexually active must use highly effective methods of&#xD;
             contraception throughout the study and for at least four months following the last&#xD;
             dose of study treatment. Male participants must agree not to donate sperm during the&#xD;
             study treatment period.&#xD;
&#xD;
          -  Written informed consent signed in accordance with federal, local, and institutional&#xD;
             guidelines.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Metastatic uveal or ocular melanoma.&#xD;
&#xD;
          -  Active central nervous system (CNS) metastases or other CNS (e.g., meningeal)&#xD;
             involvement.&#xD;
&#xD;
          -  Participants must have resolution or improvement of immune-mediated treatment related&#xD;
             adverse reactions related to prior treatment(s) to Grade ≤1 without steroid&#xD;
             maintenance therapy or his or her previous baseline prior to the corresponding CPI&#xD;
             therapy&#xD;
&#xD;
             a. History of immune-mediated treatment related adverse reactions leading to&#xD;
             discontinuation of prior anti-programmed death protein 1 (PD-1), anti-programmed death&#xD;
             protein ligand 1 (PD-L1), or anti programmed death protein ligand 2 (PD-L2) monoclonal&#xD;
             antibodies (mAbs) or severe hypersensitivity reaction to any mAb or any excipients&#xD;
             which in the opinion of the Investigator precludes future use of anti-PD-1/PDL1&#xD;
             therapy.&#xD;
&#xD;
          -  Concurrent systemic steroid therapy higher than physiologic dose (&gt;10 milligrams per&#xD;
             day [mg/day] of prednisone or equivalent).&#xD;
&#xD;
          -  Previous treatment with selinexor or other exportin 1 (XPO1) inhibitors.&#xD;
&#xD;
          -  Insufficient time since or not recovered from procedures or anti-cancer therapy,&#xD;
             defined as:&#xD;
&#xD;
               1. Not recovered from major surgery ≤28 days prior to Day 1 dosing. Minor&#xD;
                  procedures, such as biopsies, dental work, or placement of a port or intravenous&#xD;
                  (IV) line for infusion are permitted.&#xD;
&#xD;
               2. Have ongoing clinically significant anti-cancer therapy-related toxicities Common&#xD;
                  Terminology Criteria for Adverse Events (CTCAE) Grade &gt;1. In specific cases,&#xD;
                  participants whose toxicity has stabilized or with Grade 2 non-hematologic&#xD;
                  toxicities can be allowed following documented approval by the Sponsor's Medical&#xD;
                  Monitor&#xD;
&#xD;
               3. Had last dose of previous anti-cancer therapy ≤14 days prior to Day 1 dosing&#xD;
&#xD;
               4. Palliative radiotherapy &gt;14 days prior to the study is allowed&#xD;
&#xD;
               5. Received investigational drugs in other clinical trials within 28 days, or 5&#xD;
                  half-lives of the investigational drug (whichever is shorter), prior to Cycle 1&#xD;
                  Day 1 (C1D1).&#xD;
&#xD;
          -  Live-attenuated vaccine (e.g., nasal spray influenza vaccine) ≤14 days prior to the&#xD;
             intended C1D1.&#xD;
&#xD;
          -  Impairment of gastrointestinal (GI) function or GI disease that could significantly&#xD;
             alter the absorption of selinexor (e.g., vomiting, or diarrhea that is CTCAE version&#xD;
             5.0 grade &gt;1).&#xD;
&#xD;
          -  Life expectancy less than (&lt;) 4 months based on the opinion of the Investigator&#xD;
&#xD;
          -  Active pneumonitis requiring steroid therapy.&#xD;
&#xD;
          -  Uncontrolled (i.e., clinically unstable) infection requiring parenteral antibiotics,&#xD;
             antivirals, or antifungals within 7 days prior to first dose of study treatment;&#xD;
             however, prophylactic use of these agents is acceptable (including parenteral).&#xD;
&#xD;
          -  Any life-threatening illness, medical condition, or organ system dysfunction which, in&#xD;
             the Investigator's opinion, could compromise the participant's safety, prevent the&#xD;
             participant from giving informed consent, or being compliant with the study&#xD;
             procedures.&#xD;
&#xD;
          -  Female participants who are pregnant or lactating.&#xD;
&#xD;
          -  Active hepatitis B virus treated with antiviral therapy for hepatitis B within 8 weeks&#xD;
             with a viral load &gt;100 international units per milliliter (IU/mL).&#xD;
&#xD;
          -  Untreated hepatitis C virus positive without documentation of negative viral load per&#xD;
             institutional standard.&#xD;
&#xD;
          -  Human immunodeficiency virus positive with CD4+T-cells ≤350 cells per microliter,&#xD;
             positive viral load per institutional standard, and a history of acquired&#xD;
             immunodeficiency syndrome defining opportunist infections in the last year.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jatin Shah, Chief Medical Officer, MD</last_name>
    <phone>(617) 658-0600</phone>
    <email>jshah@karyopharm.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Sharon Shacham, Chief Scientific Officer, PhD</last_name>
    <phone>(617) 658-0600</phone>
    <email>sshacham@karyopharm.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>The Oncology Institute of Hope and Innovation</name>
      <address>
        <city>Pasadena</city>
        <state>California</state>
        <zip>91105</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kirsten Bettino</last_name>
      <email>kbettino@airesearch.us</email>
    </contact>
    <investigator>
      <last_name>Amitabha Mazumder, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>BRCR Global</name>
      <address>
        <city>Plantation</city>
        <state>Florida</state>
        <zip>33322</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Valeria Moreno</last_name>
      <email>vmoreno@brcrglobal.com</email>
    </contact>
    <investigator>
      <last_name>Harshad Amin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Minnesota Oncology Hematology</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55404</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lynn Anderson</last_name>
      <email>lynn.anderson@usoncology.com</email>
    </contact>
    <investigator>
      <last_name>Timothy Larson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Great Plains Health</name>
      <address>
        <city>North Platte</city>
        <state>Nebraska</state>
        <zip>69101</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lisa Kosmacek, RN</last_name>
      <email>kosmacekl@gphealth.org</email>
    </contact>
    <investigator>
      <last_name>Kartik Anand, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>John Theurer Cancer Center at Hackensack University Medical Center</name>
      <address>
        <city>Hackensack</city>
        <state>New Jersey</state>
        <zip>07601</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Danielle Blair</last_name>
      <email>danielle.blair@hmhn.org</email>
    </contact>
    <investigator>
      <last_name>Andrew Pecora, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rutgers Cancer Institute of New Jersey</name>
      <address>
        <city>New Brunswick</city>
        <state>New Jersey</state>
        <zip>08901</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Edwin Zambrano-Acosta</last_name>
      <email>ez148@rutgers.edu</email>
    </contact>
    <investigator>
      <last_name>Adam Berger, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>New York Oncology Hematology</name>
      <address>
        <city>Albany</city>
        <state>New York</state>
        <zip>12206</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amy Zuchelkowski</last_name>
      <email>Amy.Zuchelkowski@usoncology.com</email>
    </contact>
    <investigator>
      <last_name>Stephen Wrzesinski, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>OH Care Clinical Trials</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45242</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eric Clayton</last_name>
      <email>Eric.Clayton@usoncology.com</email>
    </contact>
    <investigator>
      <last_name>Suzanne Partridge, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic Foundation</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44144</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lucy McCahon</last_name>
      <email>mccahol@ccf.org</email>
    </contact>
    <investigator>
      <last_name>Brian Gastman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Texas Oncology-Austin Central</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78731</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Francisca Fernandez</last_name>
      <email>Francisca.Fernandez@usoncology.com</email>
    </contact>
    <investigator>
      <last_name>Jeffrey Yorio, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>February 22, 2021</study_first_submitted>
  <study_first_submitted_qc>February 22, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 24, 2021</study_first_posted>
  <last_update_submitted>October 21, 2021</last_update_submitted>
  <last_update_submitted_qc>October 21, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Karyopharm</keyword>
  <keyword>Locally advanced unresectable or metastatic melanoma</keyword>
  <keyword>KPT-330</keyword>
  <keyword>Recurrent advanced melanoma</keyword>
  <keyword>Selinexor</keyword>
  <keyword>Pembrolizumab</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pembrolizumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

